At Lion TCR, over a decade’s worth of basic research, product engineering and development, and pre-clinical/clinical assessment have culminated in our leading product that harnesses the power of a patient’s own immune system to eliminate HBV-related hepatocellular carcinoma. Together with our world-renowned scientific advisors, we continue to develop novel immunotherapies against viral infections and their related cancers afflicting the Asian population.